Siegfried Opens New R&D Center for Drug Substances in Evionnaz

Siegfried AG, a prominent Contract Development and Manufacturing Organization (CDMO) headquartered in Zofingen, Switzerland, has inaugurated a new global Research and Development Center for Drug Substances in Evionnaz. This 4,500 square meter facility houses advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies. It will play a crucial role alongside the existing R&D Center in Zofingen to offer enhanced chemical process and analytical development services globally.

The new R&D Center in Evionnaz provides workspaces for over 100 specialists and has created 40 new jobs. It supports Siegfried's EVOLVE+ strategy by strengthening development excellence, particularly in phase II and III drug research. CEO Marcel Imwinkelried emphasized its significance in expanding Siegfried's capacity and solidifying its position as a leading provider in the CDMO sector.